Steering CAR T cells to distinguish friend from foe

被引：22

作者：

Caruso, Hillary G. ^{[1
]}

Heimberger, Amy B. ^{[1
]}

Cooper, Laurence J. N. ^{[1
,2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd Unit 907, Houston, TX 77030 USA

[2] Ziopharm Oncol, Boston, MA USA

来源：

ONCOIMMUNOLOGY | 2019年 / 8卷 / 10期

关键词：

Bioengineering; chimeric antigen receptor; on-target toxicity; T cell; CHIMERIC ANTIGEN RECEPTOR; MESSENGER-RNA; ANTITUMOR-ACTIVITY; SUICIDE GENE; TUMOR; THERAPY; IMMUNOTHERAPY; LYMPHOCYTES; EXPRESSION; EXHIBIT;

D O I：

10.1080/2162402X.2016.1271857

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CD19-specific chimeric antigen receptor (CAR)(+) T cells have demonstrated clinical efficacy and long-lasting remissions, concomitant with tolerable normal B-cell aplasia. However, many tumor-associated antigens (TAAs) are expressed on normal tissues, the destruction of which would lead to intolerable toxicity. Thus, there is a need to engineer CAR(+) T cells with improved safety profiles to restrict toxicity against TAA-expressing normal tissues. Bioengineering approaches include: (i) targeting CAR(+) T cells to the tumor site, (ii) limiting CAR(+) T-cell persistence, and (iii) restricting CAR activation. We review and evaluate strategies to engineer CAR(+) T cells to reduce the potential of on-target, off-tissue toxicity.

引用

页数：10

共 63 条

[1] Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity [J].

Adusumilli, Prasad S. ;

Cherkassky, Leonid ;

Villena-Vargas, Jonathan ;

Colovos, Christos ;

Servais, Elliot ;

Plotkin, Jason ;

Jones, David R. ;

Sadelain, Michel .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (261)

[2] Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma [J].

Ahmed, Nabil ;

Brawley, Vita S. ;

Hegde, Meenakshi ;

Robertson, Catherine ;

Ghazi, Alexia ;

Gerken, Claudia ;

Liu, Enli ;

Dakhova, Olga ;

Ashoori, Aidin ;

Corder, Amanda ;

Gray, Tara ;

Wu, Meng-Fen ;

Liu, Hao ;

Hicks, John ;

Rainusso, Nino ;

Dotti, Gianpietro ;

Mei, Zhuyong ;

Grilley, Bambi ;

Gee, Adrian ;

Rooney, Cliona M. ;

Brenner, Malcolm K. ;

Heslop, Helen E. ;

Wels, Winfried S. ;

Wang, Lisa L. ;

Anderson, Peter ;

Gottschalk, Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) :1688-+

[3]

Ang SO, 2009, MOL THER, V17, pS25

[4] Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia [J].

Barrett, David M. ;

Liu, Xiaojun ;

Jiang, Shuguang ;

June, Carl H. ;

Grupp, Stephan A. ;

Zhao, Yangbing .

HUMAN GENE THERAPY, 2013, 24 (08) :717-727

[5] Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells [J].

Barrett, David M. ;

Zhao, Yangbing ;

Liu, Xiaojun ;

Jiang, Shuguang ;

Carpenito, Carmine ;

Kalos, Michael ;

Carroll, Richard G. ;

June, Carl H. ;

Grupp, Stephan A. .

HUMAN GENE THERAPY, 2011, 22 (12) :1575-1586

[6] Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies [J].

Beatty, Gregory L. ;

Haas, Andrew R. ;

Maus, Marcela V. ;

Torigian, Drew A. ;

Soulen, Michael C. ;

Plesa, Gabriela ;

Chew, Anne ;

Zhao, Yangbing ;

Levine, Bruce L. ;

Albelda, Steven M. ;

Kalos, Michael ;

June, Carl H. .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (02) :112-120

[7] Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation [J].

Berger, C ;

Flowers, ME ;

Warren, EH ;

Riddell, SR .

BLOOD, 2006, 107 (06) :2294-2302

[8] Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells [J].

Berger, Carolina ;

Sommermeyer, Daniel ;

Hudecek, Michael ;

Berger, Michael ;

Balakrishnan, Ashwini ;

Paszkiewicz, Paulina J. ;

Kosasih, Paula L. ;

Rader, Christoph ;

Riddell, Stanley R. .

CANCER IMMUNOLOGY RESEARCH, 2015, 3 (02) :206-216

[9] Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma [J].

Brown, Christine E. ;

Badie, Behnam ;

Barish, Michael E. ;

Weng, Lihong ;

Ostberg, Julie R. ;

Chang, Wen-Chung ;

Naranjo, Araceli ;

Starr, Renate ;

Wagner, Jamie ;

Wright, Christine ;

Zhai, Yubo ;

Bading, James R. ;

Ressler, Julie A. ;

Portnow, Jana ;

D'Apuzzo, Massimo ;

Forman, Stephen J. ;

Jensen, Michael C. .

CLINICAL CANCER RESEARCH, 2015, 21 (18) :4062-4072

[10] Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma [J].

Budde, Lihua E. ;

Berger, Carolina ;

Lin, Yukang ;

Wang, Jinjuan ;

Lin, Xubin ;

Frayo, Shani E. ;

Brouns, Shaunda A. ;

Spencer, David M. ;

Till, Brian G. ;

Jensen, Michael C. ;

Riddell, Stanley R. ;

Press, Oliver W. .

PLOS ONE, 2013, 8 (12)

← 1 2 3 4 5 6 7 →